Astera Labs (NASDAQ:ALAB) Now Covered by BNP Paribas Exane

BNP Paribas Exane began coverage on shares of Astera Labs (NASDAQ:ALAB) in a report published on Thursday morning, MarketBeat reports. The brokerage issued an outperform rating and a $225.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Northland Capmk upgraded shares of Astera Labs from a “hold” rating to a “strong-buy” rating in a report on Monday. Evercore ISI increased their price target on shares of Astera Labs from $104.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 6th. Susquehanna boosted their price objective on shares of Astera Labs from $80.00 to $125.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Deutsche Bank Aktiengesellschaft upped their price objective on Astera Labs from $160.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, Wall Street Zen lowered Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $187.06.

Astera Labs Stock Down 1.9%

Shares of NASDAQ:ALAB opened at $139.29 on Thursday. The company has a market cap of $23.53 billion, a P/E ratio of 125.49, a P/E/G ratio of 2.65 and a beta of 1.37. The business has a fifty day simple moving average of $186.87 and a 200-day simple moving average of $145.27. Astera Labs has a 52 week low of $47.13 and a 52 week high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. The firm had revenue of $230.58 million for the quarter, compared to analyst estimates of $206.42 million. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The firm’s quarterly revenue was up 103.9% on a year-over-year basis. During the same period last year, the company earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Sell-side analysts expect that Astera Labs will post 0.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Astera Labs

In other Astera Labs news, CEO Jitendra Mohan sold 90,459 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the transaction, the chief executive officer owned 2,080,418 shares in the company, valued at $301,015,680.42. The trade was a 4.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jack R. Lazar sold 22,500 shares of the company’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $178.42, for a total value of $4,014,450.00. Following the completion of the sale, the director directly owned 97,351 shares of the company’s stock, valued at $17,369,365.42. The trade was a 18.77% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 619,436 shares of company stock worth $96,530,060. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Astera Labs

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Clearstead Advisors LLC raised its stake in shares of Astera Labs by 13.6% during the third quarter. Clearstead Advisors LLC now owns 636 shares of the company’s stock valued at $125,000 after purchasing an additional 76 shares during the period. Great Valley Advisor Group Inc. grew its holdings in Astera Labs by 2.2% during the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,119 shares of the company’s stock valued at $372,000 after purchasing an additional 90 shares in the last quarter. Straight Path Wealth Management grew its holdings in Astera Labs by 1.5% during the 2nd quarter. Straight Path Wealth Management now owns 6,850 shares of the company’s stock valued at $619,000 after purchasing an additional 100 shares in the last quarter. Rye Brook Capital LLC increased its stake in Astera Labs by 1.1% during the 3rd quarter. Rye Brook Capital LLC now owns 9,200 shares of the company’s stock worth $1,801,000 after buying an additional 100 shares during the period. Finally, Assetmark Inc. lifted its holdings in Astera Labs by 374.1% in the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock worth $25,000 after buying an additional 101 shares in the last quarter. 60.47% of the stock is owned by institutional investors and hedge funds.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.